RNAI rally underway

Very promising results from Alnylam that may put a fire under all RNAI stocks :

Alnylam Reports Positive Results from Ongoing Phase 2 Open-Label Extension (OLE) Studies for Patisiran and Revusiran, in Development for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
– Patisiran Demonstrates Continued Evidence for Potential Halting of Neuropathy Progression and First-Ever Results Showing Statistically Significant Improvement in Nerve Fiber Density in Patients with Familial Amyloidotic Polyneuropathy (FAP) –
– Patisiran APOLLO Trial on Track to Complete Enrollment in Next 3-4 Months;
if Positive, Expect New Drug Application (NDA) Filing in 2017 –
– Revusiran Demonstrates Robust and Sustained Knockdown of Serum TTR of up to 98%, Representing Longest Human Target Gene Knockdown Experience with a GalNAc-siRNA Conjugate, and is Generally Well Tolerated in Majority of Patients with ATTR Cardiac Amyloidosis out to 10 Months of Treatment